Submitted by reuters8361 in health
Forty percent of patients who filled a prescription for Novo Nordisk's <a href="https://www.reuters.com/markets/companies/NOVOb.CO" target="_blank">(NOVOb.CO)</a> Wegovy to treat obesity in 2021 or 2022 were still taking it a year later, more than three times…